ARM Holdings PLC Sponsored ADR ARM 深 沪
等待开盘 02-02 09:30:00 美东时间
105.36
-3.070
-2.83%
华盛通- 最 高108.00
- 今 开107.09
- 成交量 495.07万股
- 最 低 105.03
- 昨 收 108.43
- 总市值 1115.76亿
- 52周最高 183.16
- 市盈率 静 141.40
- 换手率 0.47%
- 52周最低 80.00
- 委 比 -94.05%
- 总股本 10.59亿
- 历史最高 188.75
- 量 比 0.85
- 振 幅 2.74%
- 历史最低 46.50
- 每 手 1
- 风险率 20.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Decoding ARM Holdings's Options Activity: What's the Big Picture?
Financial giants have made a conspicuous bearish move on ARM Holdings. Our anal...
01-24 01:00
Peering Into ARM Holdings PLC's Recent Short Interest
ARM Holdings PLC's (NYSE:ARM) short interest as a percent of float has risen 11...
01-23 04:00
美股盘前 | Venture Global涨10.28%，杭庭顿控股涨6.23%
Venture Global涨10.28%；杭庭顿控股涨6.23%；Moderna涨5.44%
01-22 17:22
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
Arm Holdings Stock Jumps As Analyst Flags Significant Upside
ARM Holdings PLC (NASDAQ:ARM) shares are trading higher on Tuesday following an analyst upgrade. Here's what you need to know.
01-22 03:04
This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-21 20:07
Susquehanna Upgrades ARM Holdings to Positive, Maintains Price Target to $150
Susquehanna analyst Chris Rolland upgrades ARM Holdings (NASDAQ:ARM) from Neutral to Positive and maintains the price target from $150 to $150.
01-21 19:41
美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
